Novavax | NVAX - Zahlungsmittel Und Äquivalente





Zahlungsmittel Und Äquivalente Veränderung Datum
Adma Biologics USD 87.63M 26.24M 2025-12
Agenus USD 3.46M 6.08M 2025-09
AstraZeneca USD 8.14B 1.08B 2025-09
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
Cassava Sciences USD 106.08M 6.3M 2025-09
Geron USD 79.44M 553K 2025-12
GlaxoSmithKline GBP 3.3B 303M 2025-09
MannKind USD 74.88M 52.51M 2025-12
Merck USD 18.17B 10.16B 2025-09
Minerva Neurosciences USD 82.3M 70.02M 2025-12
Moderna USD 2.6B 1.46B 2025-12
Novartis USD 9.56B 2.9B 2025-09
Novavax USD 240.63M 27.39M 2025-12
Pfizer USD 1.34B 295M 2025-09
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
TG Therapeutics USD 199.51M 21.2M 2025-12